We are pleased to announce that we have developed an Almac optimised workflow for the Illumina TruSeq® RNA Exome Panel for use in biomarker discovery and translational research.

Current RNA panel solution – RUO

Almac Diagnostics has a proven ability to discover, develop and validate high quality, innovative RNA-based biomarkers with an extensive track record in establishing assays across key regulatory standards. We are offering the optimised RNA Exome Panel initially as Research Use Only (RUO) – not for use in Diagnostic procedures.

Future RNA panel plans – enhanced reporting solution

Almac Diagnostics is investing in the further development of defined research content for the RNA discovery panel. We are currently developing an enhanced reporting solution with easy to interpret signature scores for key pathways and biologies within the oncology field. 

We are encouraging Pharma and Biotech companies to get in touch to discuss your requirements for future translational studies.

Read the Almac RNA Panel White Paper

Contact Us

Almac optimised workflow for TruSeq® RNA Exome Panel

The Platform

The Almac RNA Exome Panel is an optimised Next Generation Sequencing (NGS) solution built on the Illumina TruSeq® RNA Exome chemistry and run on the NextSeq500 and NextSeq550 that detects RNA gene expression from solid tumour samples.

The platform covers approximately 99% of the RefSeq Exome with sequencing data and easily interpretable gene expression matrices for use in biomarker discovery and translational research across multiple disease indications.

Data analysis and reporting is performed using an Almac customised bioinformatics pipeline implemented on DNAnexus, a global leader in biomedical informatics and data management. DNAnexus is a cloud-based NGS solution which ensures scalability and security of project data. A significant benefit of utilising DNAnexus within this offering is the flexibility of workflow optimisation and the ability to customise bespoke pipelines for quality control, alignment & expression estimation.

View Panel Summary Sheet

At a Glance

  • Illumina enrichment based targeted NGS panel processed on the NextSeq500 and NextSeq550
  • Covers >21,000 genes from the RefSeq Exome
  • Optimised for use with FFPE tissue for analysis of RNA
  • Compatible with challenging sample types
  • Compatible with other tissue types such as fresh frozen
  • Established process controls included within each processing batch
  • Robust quality control pipelines optimised for core quality metrics including:
    •  -sample and library QC
    •  -sequencing run QC
    •  -post sequencing/ alignment QC
  • Results in highly repeatable and reproducible gene expression data in comparison to other RNA expression platforms.

Key Benefits

  • High quality service for profiling gene expression data from solid tissue types
  • Optimised protocol maximising on pass rates and sequencing data quality from challenging sample types, reducing sample attrition
  • Highly repeatable and reproducible gene expression data
  • Provision of raw data for research use
  • Requires minimal sample material
  • Evaluation of multiple biologies on one panel
  • Almac customised bioinformatics pipeline using a cloud-based solution (DNAnexus)

Key Facts

Metric RNA Exome Discovery Panel
Tissue Type FFPE (or FF)
Recommended Tissue Requirements 1mm³ FFPE Tissue (macrodissected)
Input Material RNA
Recommended Input Requirements 20-100 ng (dependent on DV200 sample quality)
Raw Data Provided Yes- FASTQ and BAM files
Customisable Reporting Yes
Bioinformatics Applications Cloud based RNAseq pipeline delivered via DNAnexus

In the Press


Almac Diagnostics Partners with DNAnexus to Power Clinical Trial Assay Development

Almac Trusight diagnostics in the lab

Almac Diagnostics, a global precision medicine company, has selected Clinical Trial Solution (CTS), a product launched today by DNAnexus, the global leader in biomedical informatics and data management. Implementation of this product will enable Almac to streamline the use of next-generation sequencing (NGS) data in regulated clinical trials.